BCRX BioCryst Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · SEC EDGAR पर देखें ↗ बंद अक्ट 2, 2026 10-K/10-Q अग 5, 2026
$8.17
· 52 सप्ताह की सीमा का %
· निम्न से ऊपर
· उच्च तक
$6.0052w निम्न
$11.2252w उच्च
मार्केट कैप (MRQ)
$2.09B
P/E (TTM)
-5.5
EPS (TTM)
$-1.49
राजस्व (TTM)
$941M
आपके बैज
52W रेंज
$6–$11
विश्लेषक रेटिंग
BUY
मूल्य लक्ष्य
$21
P/E
-5.5
ROE
87.8%
शुद्ध लाभ मार्जिन
-40.9%
आपकी बैज स्ट्रिप खाली है — इस पेज पर कहीं भी एक मीट्रिक पिन करें।
BCRX स्टॉक स्नैपशॉट मूल्य, बाजार पूंजीकरण, P/E, EPS, ROE, ऋण/इक्विटी, 52-सप्ताह की सीमा
मूल्य
$8.17
मार्केट कैप (MRQ)
$2.09B
P/E (TTM)
-5.5
EPS (TTM)
$-1.49
राजस्व (TTM)
$941M
ROE (TTM)
87.8%
D/E ऋण/इक्विटी (MRQ)
-0.9
52W रेंज
$6–$11
BCRX स्टॉक मूल्य चार्ट तकनीकी संकेतकों के साथ दैनिक OHLCV — पैन, ज़ूम और अपना दृश्य कस्टमाइज़ करें
सीमा
बार
बार ग्रैन्युलैरिटी चयनित अवधि के अनुसार अनुकूलित होती है — बार के लिए ओपन/हाई/लो/क्लोज देखने के लिए चार्ट पर होवर करें।
BioCryst Pharmaceuticals, Inc. - Common Stock के बारे में विकिपीडिया से कंपनी का अवलोकन
BioCryst Pharmaceuticals, Inc. is an American pharmaceutical company headquartered in Durham, North Carolina. The company is a commercial stage biotech company that focuses on developing and commercializing medicines for hereditary angioedema (HAE) and other rare diseases. BioCryst's antiviral drug peramivir (Rapivab) was approved by the FDA in December 2014 and berotralstat (ORLADEYO) was approved in December 2020.
History
The company was founded in 1986 by Charles E. Bugg and John A. Montgomery. In March 1994, BioCryst became a public company when it completed an initial public offering by listing its shares on the NASDAQ stock exchange. In 2008, the company was named one of the fastest growing companies by Deloitte & Touche in its 2008 list of Technology Fast 500.
In October 2010, BioCryst announced its headquarters would move to Durham, North Carolina, where the company has had an office since 2006. In January 2018, BioCryst signed a definitive merger agreement with Idera Pharmaceuticals, with plans for the combined company to change its name and move to Pennsylvania. However, BioCryst shareholders voted down the merger in July.
Pipeline
BioCryst’s core development programs include:
Berotralstat (BCX7353), an oral inhibitor of plasma kallikrein for prevention and treatment of hereditary angioedema (HAE).
FDA has approved Expanded Access Program for berotralstat for eligible patients in the United States.
Berotralstat has a PDUFA date for FDA approval on December 3, 2020.
On December 3, 2020, the FDA approved berotralstat as the first oral hereditary angioedema prophylaxis.
BCX9930, an oral Factor D inhibitor for the treatment of complement-mediated diseases.
FDA has granted Fast Track designation for BCX9930, for the treatment of paroxysmal nocturnal hemoglobinuria (PNH).
BCX9250, an oral ALK-2 inhibitor for treatment of fibrodysplasia ossificans progressiva (FOP).
Galidesivir (BCX4430) is a broad-spectrum antiviral in advanced development for the treatment of viruses including SARS-CoV-2 (the cause of COVID-19), Ebola, Marburg, Yellow Fever and Zika.
Galidesivir was safe and generally well tolerated in Phase 1 clinical safety and pharmacokinetics trials conducted in 2019 by both intravenous and intramuscular routes of administration in healthy human subjects.
In animal studies, galidesivir has demonstrated survival benefits against a variety of serious pathogens, including Ebola, Marburg, Yellow Fever and Zika viruses.
BioCryst is developing galidesivir in collaboration with U.S. government agencies and other institutions.
In September 2013, NIAID contracted with BioCryst for the development of galidesivir as a treatment for Marburg virus disease and potentially for other filoviruses, including Ebola virus.
In March 2015, BioCryst announced that the Biomedical Advanced Research and Development Authority (BARDA) within the U.S. Department of Health & Human Services’ Office of the Assistant Secretary for Preparedness and Response (ASPR) has awarded BioCryst a contract for the continued development of galidesivir as a potential treatment for diseases caused by RNA pathogens, including filoviruses.
In April 2020, BioCryst began enrollment of a randomized, double-blind, placebo-controlled clinical trial to assess the safety, clinical impact and antiviral effects of galidesivir in patients with COVID-19. This clinical trial is (NCT03891420) is being funded by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health. The company later made the decision to cease conducting further trials.
स्रोत: विकिपीडिया (अंग्रेज़ी), CC BY-SA 4.0 · विकिपीडिया पर देखें ↗
क्षेत्रHealthcare
उद्योगBiotechnology
कर्मचारी435
देशUS
10-वर्षीय प्रदर्शन राजस्व, शुद्ध आय, मार्जिन और ईपीएस रुझान
राजस्व$875M2016-12-31 → 2025-12-31
EPS$1.212020-12-31 → 2025-12-31
फ्री कैश फ्लो$345M2016-12-31 → 2025-12-31
शुद्ध मार्जिन-40.9%2016-12-31 → 2025-12-31
मूल्यांकन और अनुपात
मूल्यांकन P/E, P/S, P/B, EV/EBITDA अनुपात — क्या स्टॉक महंगा है या सस्ता?
| मेट्रिक | 5Y रुझान | BCRX | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| P/E (TTM) | -5.55Y औसत ≈-7.6 | ≈-7.6 | · | · | |
| P/S (TTM) | 2.25Y औसत ≈6.7 | ≈6.7 | 29.2 | अल्पमूल्यित | |
| P/B (MRQ) | -4.65Y औसत ≈-10.2 | ≈-10.2 | · | · | |
| EV / EBITDA | 5.35Y औसत ≈-281.5 | ≈-281.5 | · | · | |
| मूल्य / FCF (TTM) | 5.65Y औसत ≈-13.6 | ≈-13.6 | · | · | |
| मूल्य / नकदी प्रवाह (TTM) | 5.55Y औसत ≈-13.9 | ≈-13.9 | · | · | |
| EV / राजस्व (TTM) | 2.35Y औसत ≈6.3 | ≈6.3 | · | · | |
| EV / FCF (TTM) | 5.75Y औसत ≈-14.4 | ≈-14.4 | · | · |
सहकर्मी माध्यिका को प्रति मीट्रिक मानकीकृत आधार पर गणना की जाती है और यह हमेशा इस स्टॉक के लिए दिखाए गए TTM/MRQ आधार से मेल नहीं खा सकती है।
लाभप्रदता सकल, परिचालन और शुद्ध मार्जिन; ROE, ROA, ROIC
| मेट्रिक | 5Y रुझान | BCRX | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| परिचालन मार्जिन (TTM) | -33.3%5Y औसत ≈-32.2% | ≈-32.2% | -1041.7% | शीर्ष स्तर | |
| EBITDA Margin (EBITDA मार्जिन) | 39.1%5Y औसत ≈-31.8% | ≈-31.8% | -1041.7% | शीर्ष स्तर | |
| प्रीटैक्स मार्जिन (TTM) | -40.5%5Y औसत ≈-52.6% | ≈-52.6% | -493.4% | शीर्ष स्तर | |
| शुद्ध लाभ मार्जिन (TTM) | -40.9%5Y औसत ≈-53.3% | ≈-53.3% | -990.1% | शीर्ष स्तर | |
| ROA (TTM) | -75.8%5Y औसत ≈-18.2% | ≈-18.2% | -40.3% | शीर्ष स्तर | |
| ROE (TTM) | 87.8%5Y औसत ≈42.1% | ≈42.1% | -55.6% | कमजोर | |
| ROIC | -282.4%5Y औसत ≈-118.5% | ≈-118.5% | -55.2% | कमजोर |
वित्तीय स्वास्थ्य ऋण, तरलता, शोधन क्षमता — बैलेंस शीट की मजबूती
| मेट्रिक | 5Y रुझान | BCRX | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| ऋण / इक्विटी (MRQ) | -0.95Y औसत ≈-0.7 | ≈-0.7 | 0.0 | कम ऋण | |
| वर्तमान अनुपात (MRQ) | 2.35Y औसत ≈3.7 | ≈3.7 | 6.7 | कम तरलता | |
| त्वरित अनुपात (MRQ) | 2.25Y औसत ≈2.5 | ≈2.5 | 4.5 | कम तरलता | |
| दीर्घकालिक ऋण / इक्विटी (MRQ) | -0.95Y औसत ≈-0.7 | ≈-0.7 | 0.2 | कम ऋण |
विकास राजस्व, EPS और शुद्ध आय वृद्धि: YoY, 3Y CAGR, 5Y CAGR
| मेट्रिक | 5Y रुझान | BCRX | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| Revenue YoY (राजस्व YoY) | 94.1%5Y औसत ≈201.4% | ≈201.4% | · | · | |
| Revenue CAGR 3Y (राजस्व CAGR 3Y) | 47.8%5Y औसत ≈85.0% | ≈85.0% | · | · | |
| Revenue CAGR 5Y (राजस्व CAGR 5Y) | 117.9% | · | · | · |
पूंजी दक्षता एसेट टर्नओवर, इन्वेंटरी टर्नओवर, प्राप्य टर्नओवर
| मेट्रिक | 5Y रुझान | BCRX | 5Y औसत | सहकर्मी माध्यिका | निर्णय |
|---|---|---|---|---|---|
| Asset Turnover (परिसंपत्ति टर्नओवर) | 1.75Y औसत ≈0.8 | ≈0.8 | 0.1 | शीर्ष स्तर | |
| Inventory Turnover (इन्वेंटरी टर्नओवर) | 2.85Y औसत ≈0.9 | ≈0.9 | · | · | |
| Receivables Turnover (प्राप्य टर्नओवर) | 9.45Y औसत ≈7.4 | ≈7.4 | · | · | |
| Revenue / Employee (राजस्व / कर्मचारी (रिपोर्ट की गई हेडकाउंट, यफाइनांस)। व्युत्पन्न — संग्रहीत SEC-XBRL अवधारणा नहीं है।) | ≈$2.0M | · | · | · |
मान · ≈ 5Y औसत · उद्योग माध्य · माध्य के सापेक्ष निर्णय
Earnings History EPS वास्तविक बनाम अनुमान, आश्चर्य %, बीट दर, अगली आय तिथि
औसत आश्चर्य
23.2%
अगली रिपोर्ट
नव 02, 2026
| Period | रिपोर्ट | EPS Actual | EPS अनुमान | आश्चर्य |
|---|---|---|---|---|
| 30 जून 2026 | अग 3, 2026 | $0.30 | $0.12 | 148.1% |
| 31 मार्च 2026 | $-0.09 | $0.05 | -281.8% | |
| 31 दिसमबर 2025 | $0.01 | $0.04 | -74.1% | |
| 30 सितमबर 2025 | $0.06 | $0.04 | 67.1% | |
| 30 जून 2025 | $0.04 | $0.01 | 179.7% | |
| 31 मार्च 2025 | $0.00 | $-0.07 | 100.0% |
पूर्ण मौलिक सभी मेट्रिक्स प्रति वर्ष — आय विवरण, बैलेंस शीट, नकदी प्रवाह
आय विवरण
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Cost of Revenue | $19M | $12M | $4M | $6M | $7M | $2M | $4M | · | $1M | $2M | $1M | $1.0K | |
| R&D Expense | $166M | $175M | $217M | $253M | $209M | $123M | $107M | $85M | $67M | $61M | $73M | $52M | |
| SG&A Expense | $349M | $266M | $214M | $159M | $119M | $68M | $37M | $30M | $14M | $11M | $13M | $7M | |
| Operating Expenses | $534M | $453M | $435M | $419M | $335M | $193M | $148M | $115M | $83M | $75M | $88M | $59M | |
| Operating Income | $341M | $-3M | $-104M | $-148M | $-178M | $-175M | $-99M | $-94M | $-57M | $-49M | $-39M | $-46M | |
| Interest Expense | · | · | $108M | $99M | $59M | $15M | $12M | $9M | $9M | $6M | $5M | $5M | |
| Other Non-op | $-74M | $-84M | $-123M | $-96M | · | · | · | · | · | · | · | · | |
| Pretax Income | $267M | $-87M | $-226M | $-244M | $-182M | $-183M | $-109M | · | · | · | · | · | |
| Income Tax | $4M | $2M | $310.0K | $3M | $2M | $0 | $0 | $0 | $0 | $0 | $0 | · | |
| Net Income | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| EPS (Basic) | $1.26 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| EPS (Diluted) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | · | · | · | · | · | · | |
| Shares (Basic) | 209,893,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | · | · | · | · | · | · | |
| Shares (Diluted) | 218,581,000 | 206,696,000 | 192,198,000 | 185,908,000 | 179,117,000 | 167,267,000 | 115,600,000 | 103,185,000 | 84,451,000 | 73,699,000 | 72,901,000 | 66,773,000 | |
| EBITDA | $342M | $-1M | $-102M | $-147M | $-177M | $-174M | $-99M | $-93M | · | $-48M | $-39M | $-46M |
बैलेंस शीट
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $90M | $105M | $111M | $305M | $504M | $272M | $114M | $27M | $50M | $22M | $29M | $55M | |
| Short-term Investments | $185M | $216M | · | · | · | · | · | · | · | · | · | · | |
| Receivables | $107M | $79M | $57M | $51M | $29M | $9M | $22M | $4M | $6M | $9M | $6M | $4M | |
| Inventory | $5M | $8M | $29M | $28M | $16M | $7M | $0 | $2M | · | $500.0K | $2M | $683.0K | |
| Prepaid Expense | $17M | $14M | $20M | $13M | $10M | $6M | $4M | $2M | $1M | $1M | $3M | $6M | |
| Current Assets | $404M | $422M | $496M | $516M | $566M | $324M | $164M | $114M | $125M | $67M | $64M | $89M | |
| PP&E (Net) | $9M | $8M | $8M | $9M | $9M | $7M | $7M | $9M | $10M | $10M | $5M | $207.0K | |
| PP&E (Gross) | $18M | $20M | $19M | $18M | $17M | $14M | $14M | $15M | $15M | $15M | $19M | $14M | |
| Accum. Depreciation | $9M | $12M | $11M | $10M | $8M | $7M | $7M | $6M | $5M | $5M | $14M | $14M | |
| Other Non-current Assets | $6M | $5M | $80.0K | $7M | $6M | $4M | $4M | $978.0K | $2M | $4M | $5M | $6M | |
| Total Assets | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Accounts Payable | $16M | $12M | $21M | $14M | $28M | $19M | $14M | $8M | $6M | $4M | $9M | $3M | |
| Accrued Liabilities | $126M | $113M | $103M | $88M | $73M | $34M | $21M | $16M | $13M | $11M | $16M | $11M | |
| Short-term Debt | · | · | · | · | · | $30M | $30M | $29M | $29M | $28M | $28M | $30M | |
| Current Liabilities | $196M | $160M | $150M | $106M | $104M | $106M | $92M | $69M | $75M | $54M | $62M | $57M | |
| Capital Leases | $9M | $8M | $8M | $4M | $6M | $4M | · | · | · | · | · | · | |
| Other Non-current Liabilities | · | · | · | · | · | · | · | $3M | · | · | · | · | |
| Total Liabilities | $633M | $966M | $972M | · | · | · | · | · | · | · | · | · | |
| Long-term Debt | · | · | · | · | $298M | $123M | $50M | $30M | $23M | $23M | · | · | |
| Total Debt | $0 | $315M | $303M | $232M | $136M | $150M | $30M | $29M | · | $28M | $30M | $30M | |
| Common Stock | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $1M | $984.0K | $738.0K | $734.0K | $720.0K | |
| Paid-in Capital | $1.38B | $1.29B | $1.22B | $1.16B | $1.10B | $1.00B | $877M | $780M | $715M | $567M | $558M | $543M | |
| Retained Earnings | $-1.51B | $-1.77B | $-1.68B | $-1.45B | $-1.21B | $-1.02B | $-841M | $-732M | $-632M | $-566M | $-511M | $-468M | |
| AOCI | $38.0K | $921.0K | $1M | $26.0K | $177.0K | $3.0K | $39.0K | $-297.0K | $-243.0K | $-12.0K | $-206.0K | $-130.0K | |
| Stockholders' Equity | $-119M | $-476M | $-456M | $-295M | $-107M | $-19M | $38M | $49M | $84M | $2M | $48M | $76M | |
| Liabilities + Equity | $514M | $490M | $517M | $550M | $588M | $335M | $175M | $147M | $178M | $90M | $122M | $137M | |
| Shares Outstanding | 213,060,000 | 208,543,000 | 205,771,000 | 187,906,000 | 184,350,000 | 176,883,000 | 154,082,000 | 110,063,000 | 98,411,000 | 73,782,000 | 73,355,000 | 71,955,000 |
नकदी प्रवाह
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $1M | $2M | $1M | $777.0K | $748.0K | $724.0K | $770.0K | $704.0K | $483.0K | $180.0K | $177.0K | |
| Stock-based Comp | $85M | $65M | $56M | $45M | $35M | $15M | $18M | $9M | $13M | $8M | $10M | $10M | |
| Deferred Tax | $-1M | $-354.0K | $-682.0K | $11.0K | $-159.0K | · | · | · | · | · | · | · | |
| Other Non-cash | $-2M | $-29M | $75M | $39M | $6M | $30M | $870.0K | $-1M | · | $-7M | $20M | $-4M | |
| Operating Cash Flow | $347M | $-52M | $-95M | $-162M | $-142M | $-135M | $-90M | $-93M | $-41M | $-53M | $-13M | $-39M | |
| CapEx | $2M | $1M | $2M | $1M | $2M | $514.0K | $343.0K | $366.0K | $328.0K | $5M | $5M | $106.0K | |
| Investing Cash Flow | $-14M | $53M | $-131M | $-128M | $16M | $-7M | $78M | $5M | $-65M | $23M | $-18M | · | |
| Debt Issued | $0 | $0 | $300M | $73M | $0 | · | · | · | · | · | · | · | |
| Net Debt Issued | $-300M | $0 | $300M | · | · | · | · | · | · | · | · | · | |
| Stock Issued | · | · | $0 | $0 | $50M | $93M | $58M | $53M | $134M | · | · | $107M | |
| Net Stock Activity | · | · | $0 | $0 | $50M | $93M | $58M | $53M | · | · | · | $107M | |
| Financing Cash Flow | $-350M | $-6M | $32M | $88M | $360M | $301M | $99M | $63M | $136M | $23M | $5M | · | |
| Net Change in Cash | $-15M | $-6M | $-194M | $-201M | $233M | $159M | $87M | $-25M | $30M | $-7M | $-26M | $33M | |
| Taxes Paid | $3M | $2M | $1M | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | $345M | $-53M | $-97M | $-163M | $-145M | $-138M | $-90M | $-93M | · | $-59M | $-18M | $-39M | |
| Levered FCF | · | · | $-206M | $-263M | $-205M | $-152M | · | · | · | · | · | · |
लाभप्रदता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% | -981.1% | -203.7% | -456.2% | · | -184.4% | -81.7% | -336.4% | |
| Net Margin | 30.2% | -19.7% | -68.4% | -91.2% | -117.1% | -1026.4% | -223.0% | -490.2% | · | -209.2% | -89.1% | -332.1% | |
| Pretax Margin | 30.6% | -19.3% | -68.3% | -90.2% | -115.7% | -1026.4% | · | · | · | · | · | · | |
| EBITDA Margin | 39.1% | -0.29% | -30.8% | -54.3% | -112.6% | -976.9% | -202.2% | -452.5% | · | -182.6% | -81.4% | -335.0% | |
| ROA | 52.5% | -17.6% | -42.5% | -43.4% | -39.9% | -71.7% | -67.6% | -62.3% | · | -52.0% | -32.9% | -48.7% | |
| ROE | -97.6% | 18.8% | 52.3% | 92.0% | 144.9% | -2543.5% | 7257.4% | -165.8% | · | -223.7% | -69.8% | -121.3% | |
| ROIC | -282.4% | 1.6% | 68.2% | 238.4% | -618.4% | -133.9% | · | · | · | · | · | · |
तरलता और शोधन क्षमता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 | 3.1 | 1.8 | 1.6 | · | 1.2 | 1.0 | 1.5 | |
| Quick Ratio | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 | 2.7 | 1.5 | 0.4 | · | 0.6 | 0.5 | 0.9 | |
| Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -7.8 | 0.8 | 0.6 | · | 17.9 | 0.6 | 0.4 | |
| LT Debt / Equity | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 | -6.2 | · | · | · | · | · | · | |
| Interest Coverage | · | · | -1.0 | -1.5 | -3.0 | -12.1 | -8.4 | -10.3 | · | -7.5 | -7.6 | -9.2 |
दक्षता
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 1.7 | 0.9 | 0.6 | 0.5 | 0.3 | 0.1 | 0.3 | 0.1 | · | 0.2 | 0.4 | 0.1 | |
| Inventory Turnover | 2.8 | 0.4 | 0.2 | 0.3 | 0.6 | 0.4 | · | · | · | 2.2 | 1.2 | 0.0 | |
| Receivables Turnover | 9.4 | 6.6 | 6.2 | 6.8 | 8.3 | 1.2 | 3.7 | 4.0 | · | 3.5 | 9.6 | · |
प्रति शेयर
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-0.56 | $-2.28 | $-2.21 | $-1.57 | $-0.58 | $-0.11 | $0.25 | $0.45 | · | $0.02 | $0.65 | $1.05 | |
| Revenue / Share | $4.00 | $2.18 | $1.72 | $1.46 | $0.88 | $0.11 | $0.42 | $0.20 | · | $0.36 | $0.66 | · | |
| Cash Flow / Share | $1.59 | $-0.25 | $-0.49 | $-0.87 | $-0.79 | $-0.82 | $-0.77 | $-0.90 | · | $-0.73 | $-0.18 | · | |
| Cash / Share | $0.42 | $0.50 | $0.54 | $1.62 | $2.74 | $1.54 | $0.74 | $0.24 | · | $0.30 | $0.39 | $0.76 | |
| EPS (TTM) | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 | $-1.09 | $-0.61 | $-0.61 | $-0.61 | $-0.61 | $-0.60 | · |
विकास दरें
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 94.1% | 36.0% | 22.4% | 72.3% | 782.4% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | 47.8% | 42.1% | 165.0% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 117.9% | · | · | · | · | · | · | · | · | · | · | · |
मूल्यांकन (TTM)
| मेट्रिक | रुझान | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $875M | $451M | $331M | $271M | $157M | $18M | $49M | $21M | $25M | $26M | $48M | $14M | |
| Net Income TTM | $264M | $-89M | $-227M | $-247M | $-184M | $-183M | $-109M | $-101M | $-66M | $-55M | $-43M | $-45M | |
| Market Cap | $1.66B | $1.57B | $1.23B | $2.16B | $2.55B | $1.32B | $532M | $888M | · | $467M | $757M | $875M | |
| Enterprise Value | $1.39B | $1.78B | $1.43B | $2.08B | $2.18B | $1.20B | $447M | $891M | · | $473M | $758M | $850M | |
| P/E | 6.4 | -17.5 | -5.1 | -8.6 | -13.4 | -6.8 | -5.7 | -13.2 | -8.0 | -10.4 | -17.2 | · | |
| P/S | 1.9 | 3.5 | 3.7 | 8.0 | 16.2 | 74.0 | 10.9 | 43.0 | · | 17.7 | 15.7 | 64.3 | |
| P/B | -13.9 | -3.3 | -2.7 | -7.3 | -23.9 | -68.4 | 13.9 | 18.0 | · | 296.0 | 15.9 | 11.6 | |
| P / Cash Flow | 4.8 | -30.1 | -13.0 | -13.3 | -18.0 | -9.6 | -5.9 | -9.6 | · | -8.7 | -57.7 | -22.7 | |
| P / FCF | 4.8 | -29.5 | -12.7 | -13.2 | -17.7 | -9.6 | -5.9 | -9.6 | · | -8.0 | -41.5 | -22.6 | |
| EV / EBITDA | 4.1 | -1371.2 | -14.0 | -14.2 | -12.3 | -6.9 | -4.5 | -9.5 | · | -9.8 | -19.3 | -18.7 | |
| EV / FCF | 4.0 | -33.5 | -14.6 | -12.8 | -15.1 | -8.7 | -5.0 | -9.6 | · | -8.1 | -41.6 | -22.0 | |
| EV / Revenue | 1.6 | 3.9 | 4.3 | 7.7 | 13.9 | 67.1 | 9.2 | 43.1 | · | 18.0 | 15.7 | 62.5 | |
| Earnings Yield | 15.5% | -5.7% | -19.7% | -11.6% | -7.4% | -14.6% | -17.7% | -7.6% | -12.4% | -9.6% | -5.8% | · |
आय विवरण
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $218M | $156M | $407M | $159M | $163M | $146M | $132M | $117M | $109M | $93M | $93M | $87M | $82M | $69M | $80M | $76M | |
| Cost of Revenue | $4M | $5M | $10M | $2M | $3M | $5M | $6M | $3M | $2M | $1M | $2M | $1M | $894.0K | $931.0K | $2M | $4M | |
| R&D Expense | $52M | $60M | $41M | $45M | $43M | $37M | $49M | $41M | $38M | $46M | $70M | $47M | $51M | $48M | $73M | $53M | |
| SG&A Expense | $64M | $95M | $96M | $83M | $87M | $82M | $81M | $65M | $61M | $59M | $65M | $51M | $51M | $48M | $50M | $37M | |
| Operating Expenses | $120M | $858M | $146M | $130M | $134M | $124M | $136M | $109M | $101M | $107M | $136M | $99M | $103M | $97M | $126M | $93M | |
| Operating Income | $98M | $-702M | $260M | $30M | $30M | $21M | $-5M | $8M | $9M | $-14M | $-43M | $-12M | $-21M | $-28M | $-46M | $-17M | |
| Interest Expense | · | · | · | · | · | · | · | · | $25M | $25M | · | $27M | $29M | $27M | · | $25M | |
| Other Non-op | $260.0K | $-1M | $-12M | $-17M | $0 | $0 | $-21M | $-21M | $-21M | $-21M | · | · | · | · | · | · | |
| Pretax Income | $79M | $-721M | $248M | $12M | $6M | $758.0K | $-26M | $-13M | $-13M | $-35M | $-63M | $-36M | $-75M | $-53M | $-71M | $-41M | |
| Income Tax | $1M | $1M | $2M | $-769.0K | $1M | $726.0K | $804.0K | $586.0K | $172.0K | $365.0K | $-1M | $330.0K | $740.0K | $671.0K | $76.0K | $2M | |
| Net Income | $78M | $-722M | $246M | $13M | $5M | $32.0K | $-27M | $-14M | $-13M | $-35M | $-62M | $-36M | $-75M | $-53M | $-72M | $-43M | |
| EPS (Basic) | $0.31 | $-2.98 | $1.18 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| EPS (Diluted) | $0.30 | $-2.98 | $1.13 | $0.06 | $0.02 | $0.00 | $-0.13 | $-0.07 | $-0.06 | $-0.17 | $-0.31 | $-0.19 | $-0.40 | $-0.28 | $-0.38 | $-0.23 | |
| Shares (Basic) | 254,481,000 | 242,258,000 | · | 210,176,000 | 209,519,000 | 208,882,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| Shares (Diluted) | 265,165,000 | 242,258,000 | · | 219,885,000 | 219,886,000 | 215,261,000 | · | 206,905,000 | 206,425,000 | 206,064,000 | · | 189,644,000 | 189,118,000 | 188,509,000 | · | 186,180,000 | |
| EBITDA | $98M | $-702M | · | $30M | $30M | $22M | · | $8M | $9M | $-14M | · | $-12M | $-21M | $-28M | · | $-17M |
बैलेंस शीट
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $155M | $172M | $90M | $84M | $88M | $105M | $105M | $97M | $78M | $84M | $111M | $151M | $146M | $155M | $305M | $247M | |
| Short-term Investments | $198M | $67M | $185M | $129M | $172M | $190M | $216M | · | · | · | · | · | · | · | · | · | |
| Receivables | $111M | $109M | $107M | $91M | $91M | $93M | $79M | $72M | $69M | $61M | · | $54M | $58M | $49M | · | $43M | |
| Inventory | $6M | $6M | $5M | $5M | $5M | $7M | $8M | $8M | $4M | $30M | · | $30M | $27M | $27M | · | $27M | |
| Prepaid Expense | $15M | $19M | $17M | $17M | $13M | $14M | $14M | $16M | $16M | $18M | · | $20M | $14M | $15M | · | $11M | |
| Current Assets | $485M | $374M | $404M | $356M | $398M | $410M | $422M | $427M | $363M | $447M | · | $502M | $511M | $491M | · | $509M | |
| PP&E (Net) | $9M | $9M | $9M | $8M | $8M | $8M | $8M | $7M | $8M | $8M | · | $9M | $8M | $8M | · | $8M | |
| PP&E (Gross) | · | · | $18M | · | · | · | $20M | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | · | · | $9M | · | · | · | $12M | · | · | · | · | · | · | · | · | · | |
| Other Non-current Assets | $20M | $20M | $6M | $4M | $4M | $5M | $5M | $16M | $12M | $13M | · | $11M | $7M | $7M | · | $7M | |
| Total Assets | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Accounts Payable | $11M | $11M | $16M | $6M | $9M | $10M | $12M | $13M | $8M | $12M | · | $11M | $14M | $6M | · | $9M | |
| Accrued Liabilities | $122M | $119M | $126M | $119M | $107M | $93M | $113M | $104M | $90M | $79M | · | $77M | $75M | $75M | · | $69M | |
| Current Liabilities | $209M | $195M | $196M | $190M | $177M | $140M | $160M | $154M | $129M | $120M | · | $91M | $93M | $85M | · | $82M | |
| Capital Leases | $11M | $11M | $9M | $8M | $8M | $8M | $8M | $8M | $8M | $9M | · | $10M | $6M | $6M | · | $6M | |
| Total Liabilities | $1.01B | $1.02B | $633M | $834M | $879M | $932M | $966M | $960M | · | · | · | · | · | · | · | · | |
| Total Debt | $395M | $395M | · | $194M | $243M | $315M | · | $314M | $314M | $308M | · | $298M | $293M | $233M | · | $224M | |
| Common Stock | $3M | $3M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Paid-in Capital | $1.69B | $1.67B | $1.38B | $1.36B | $1.34B | $1.31B | $1.29B | $1.27B | $1.25B | $1.24B | · | $1.21B | $1.19B | $1.18B | · | $1.14B | |
| Retained Earnings | $-2.15B | $-2.23B | $-1.51B | $-1.75B | $-1.76B | $-1.77B | $-1.77B | $-1.74B | $-1.73B | $-1.72B | · | $-1.62B | $-1.58B | $-1.51B | · | $-1.38B | |
| AOCI | $-528.0K | $-368.0K | $38.0K | $1M | $2M | $1M | $921.0K | $2M | $557.0K | $771.0K | · | $800.0K | $690.0K | $585.0K | · | $-98.0K | |
| Stockholders' Equity | $-454M | $-554M | $-119M | $-388M | $-422M | $-452M | $-476M | $-469M | $-476M | $-476M | $-456M | $-411M | $-389M | $-328M | $-295M | $-243M | |
| Liabilities + Equity | $558M | $465M | $514M | $446M | $457M | $480M | $490M | $491M | $472M | $468M | · | $523M | $530M | $510M | · | $559M | |
| Shares Outstanding | 255,265,000 | 254,014,000 | 213,060,000 | 210,522,000 | 209,905,000 | 209,208,000 | 208,543,000 | 207,119,000 | 206,629,000 | 206,347,000 | 205,771,000 | 189,803,000 | 189,491,000 | 188,883,000 | 187,906,000 | 186,411,000 |
नकदी प्रवाह
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | · | · | $394.0K | $335.0K | $329.0K | $331.0K | $309.0K | $311.0K | $320.0K | $306.0K | $423.0K | $420.0K | $407.0K | $405.0K | $396.0K | $389.0K | |
| Stock-based Comp | $15M | $16M | $24M | $19M | $21M | $21M | $21M | $17M | $13M | $14M | $16M | $12M | $13M | $14M | $15M | $10M | |
| Amort. of Intangibles | $0 | $600.0K | · | · | $0 | $0 | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | · | · | · | · | $-49M | · | · | · | $-32M | · | · | · | $-9M | · | · | |
| Operating Cash Flow | $104M | $-62M | $292M | $42M | $41M | $-28M | $-5M | $8M | $-1M | $-54M | $-9M | $-20M | $-19M | $-48M | $-24M | $-32M | |
| CapEx | $209.0K | $403.0K | $802.0K | $1M | $179.0K | $143.0K | $675.0K | $59.0K | $155.0K | $235.0K | $554.0K | $987.0K | $467.0K | $160.0K | $526.0K | $175.0K | |
| Investing Cash Flow | $-110M | $-269M | $-83M | $14M | $29M | $27M | $18M | $8M | $-2M | $29M | $-28M | $23M | $-19M | $-107M | $77M | $-70M | |
| Debt Issued | $0 | $400M | · | · | $0 | $0 | $0 | $0 | · | · | $0 | $0 | · | · | $0 | $73M | |
| Net Debt Issued | · | $400M | · | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Financing Cash Flow | $-11M | $413M | $-218M | $-59M | $-74M | $529.0K | $-4M | $1M | $-2M | $-1M | $-3M | $1M | $29M | $5M | $4M | $76M | |
| Net Change in Cash | $-17M | $82M | · | · | $-17M | $558.0K | $7M | $19M | $-6M | $-26M | $-40M | $5M | $-9M | $-150M | $58M | $-26M | |
| Taxes Paid | $2M | $1M | · | · | $1M | $1.0K | · | · | · | · | · | · | · | · | · | · | |
| Free Cash Flow | · | $-62M | · | · | · | $-28M | · | · | · | $-54M | · | · | · | $-48M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-79M | · | · | · | $-75M | · | · |
लाभप्रदता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.6% | · | 6.6% | 8.0% | -15.6% | · | -13.7% | -25.1% | -41.3% | · | -23.0% | |
| Net Margin | 35.9% | -461.5% | · | 8.1% | 3.1% | 0.02% | · | -12.0% | -11.6% | -38.1% | · | -41.7% | -91.3% | -77.5% | · | -56.1% | |
| Pretax Margin | 36.4% | -460.8% | · | 7.6% | 4.0% | 0.52% | · | -11.5% | -11.4% | -37.8% | · | -41.3% | -90.4% | -76.6% | · | -54.1% | |
| EBITDA Margin | 45.1% | -448.6% | · | 18.6% | 18.2% | 14.8% | · | 6.6% | 8.0% | -15.3% | · | -13.7% | -25.1% | -40.7% | · | -23.0% | |
| ROA | 15.4% | -152.8% | · | 2.8% | 1.1% | 0.01% | · | -2.8% | -2.5% | -7.2% | · | -6.7% | -14.5% | -10.3% | · | -10.3% | |
| ROE | -17.9% | 143.5% | · | -3.0% | -1.1% | -0.01% | · | 3.2% | 2.9% | 8.8% | · | 11.1% | 25.0% | 21.7% | · | 21.8% | |
| ROIC | -164.9% | 442.9% | · | -16.3% | -13.1% | -0.66% | · | -5.2% | -5.5% | 8.7% | · | 10.7% | 21.9% | 30.0% | · | 96.3% |
तरलता और शोधन क्षमता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.3 | 1.9 | · | 1.9 | 2.2 | 2.9 | · | 2.8 | 2.8 | 3.7 | · | 5.5 | 5.5 | 5.8 | · | 6.2 | |
| Quick Ratio | 2.2 | 1.8 | · | 1.6 | 2.0 | 2.8 | · | 1.1 | 1.1 | 1.2 | · | 2.3 | 2.2 | 2.4 | · | 3.5 | |
| Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| LT Debt / Equity | -0.9 | -0.7 | · | -0.5 | -0.6 | -0.7 | · | -0.7 | -0.7 | -0.6 | · | -0.7 | -0.8 | -0.7 | · | -0.9 | |
| Interest Coverage | · | · | · | · | · | · | · | · | 0.4 | -0.6 | · | -0.4 | -0.7 | -1.0 | · | -0.7 |
दक्षता
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.4 | 0.3 | · | 0.3 | 0.4 | 0.3 | · | 0.2 | 0.2 | 0.2 | · | 0.2 | 0.2 | 0.1 | · | 0.2 | |
| Inventory Turnover | 0.7 | 0.8 | · | 0.3 | 0.6 | 0.2 | · | 0.2 | 0.1 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.2 | |
| Receivables Turnover | 2.2 | 1.5 | · | 1.9 | 2.0 | 1.9 | · | 1.9 | 1.7 | 1.7 | · | 1.8 | 1.7 | 1.6 | · | 2.2 |
प्रति शेयर
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $-1.78 | $-2.18 | · | $-1.84 | $-2.01 | $-2.16 | · | $-2.26 | $-2.30 | $-2.31 | · | $-2.17 | $-2.05 | $-1.74 | · | $-1.30 | |
| Revenue / Share | $0.82 | $0.65 | · | $0.72 | $0.74 | $0.68 | · | $0.57 | $0.53 | $0.45 | · | $0.46 | $0.44 | $0.36 | · | $0.41 | |
| Cash Flow / Share | · | $-0.26 | · | · | · | $-0.13 | · | · | · | $-0.26 | · | · | · | $-0.25 | · | · | |
| Cash / Share | $0.61 | $0.68 | · | $0.40 | $0.42 | $0.50 | · | $0.47 | $0.38 | $0.41 | · | $0.80 | $0.77 | $0.82 | · | $1.32 | |
| EPS (TTM) | $-1.49 | $-1.77 | · | $-0.05 | $-0.18 | $-0.26 | · | $-0.61 | $-0.73 | $-1.07 | · | $-1.25 | $-1.29 | $-1.21 | · | $-1.05 |
मूल्यांकन (TTM)
| मेट्रिक | रुझान | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $941M | $886M | · | $600M | $558M | $503M | · | $413M | $382M | $355M | · | $318M | $307M | $290M | · | $238M | |
| Net Income TTM | $-385M | $-458M | · | $-9M | $-36M | $-53M | · | $-124M | $-146M | $-209M | · | $-236M | $-243M | $-226M | · | $-193M | |
| Market Cap | $2.55B | $2.42B | · | $1.60B | $1.88B | $1.57B | · | $1.57B | $1.28B | $1.05B | · | $1.34B | $1.33B | $1.58B | · | $2.35B | |
| Enterprise Value | $2.60B | $2.58B | · | $1.58B | $1.86B | $1.59B | · | $1.79B | $1.51B | $1.27B | · | $1.49B | $1.48B | $1.65B | · | $2.33B | |
| P/E | -6.7 | -5.4 | · | -151.8 | -49.8 | -28.8 | · | -12.5 | -8.5 | -4.7 | · | -5.7 | -5.5 | -6.9 | · | -12.0 | |
| P/S | 2.7 | 2.7 | · | 2.7 | 3.4 | 3.1 | · | 3.8 | 3.3 | 2.9 | · | 4.2 | 4.4 | 5.4 | · | 9.9 | |
| P/B | -5.6 | -4.4 | · | -4.1 | -4.5 | -3.5 | · | -3.4 | -2.7 | -2.2 | · | -3.3 | -3.4 | -4.8 | · | -9.7 | |
| P / Cash Flow | · | -39.1 | · | · | · | -57.0 | · | · | · | -19.5 | · | · | · | -33.2 | · | · | |
| EV / Revenue | 2.8 | 2.9 | · | 2.6 | 3.3 | 3.2 | · | 4.3 | 4.0 | 3.6 | · | 4.7 | 4.8 | 5.7 | · | 9.8 | |
| Earnings Yield | -14.9% | -18.6% | · | -0.66% | -2.0% | -3.5% | · | -8.0% | -11.8% | -21.1% | · | -17.7% | -18.3% | -14.5% | · | -8.3% |
सबसे हाल की अवधि बाईं ओर · शून्य मान इस प्रकार दिखाए गए हैं ·
वित्तीय विवरण आय विवरण, बैलेंस शीट, नकदी प्रवाह — वार्षिक, पिछले 5 वर्ष
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| राजस्व | $875M | $451M | $331M | $271M | $157M |
| परिचालन मार्जिन % | 39.0% | -0.56% | -31.3% | -54.8% | -113.1% |
| शुद्ध आय | $264M | $-89M | $-227M | $-247M | $-184M |
| तनुकरणित EPS | $1.21 | $-0.43 | $-1.18 | $-1.33 | $-1.03 |
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| ऋण / इक्विटी | 0.0 | -0.7 | -0.7 | -0.8 | -1.3 |
| वर्तमान अनुपात | 2.1 | 2.6 | 3.3 | 4.9 | 5.5 |
| त्वरित अनुपात | 1.9 | 1.1 | 1.1 | 3.4 | 5.1 |
| मेट्रिक | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| फ्री कैश फ्लो | $345M | $-53M | $-97M | $-163M | $-145M |
संस्थागत मालिक (13F) 345 फाइलर्स · $2.8B कुल · तिथि अनुसार 30 सितमबर 2026
संस्थान जो अपनी तिमाही SEC फॉर्म 13F में इस स्टॉक को होल्ड करने की रिपोर्ट करते हैं। केवल लॉन्ग पोजीशन; एक ही फाइलर अलग-अलग ऑप्शन लेग्स के लिए दो बार दिखाई दे सकता है। बड़े ऑफसेटिंग पुट/कॉल लेग्स आमतौर पर मार्केट-मेकिंग या हेज्ड इन्वेंट्री को दर्शाते हैं, न कि दिशात्मक विश्वास को।
धारक
345
धारित मूल्य
$2.8B
नई स्थितियाँ
55
बाहर निकली पोजीशन
34
संस्थागत गतिविधि — Q2 2026 बनाम पिछली तिमाही
| नई स्थितियाँ | बाहर निकली पोजीशन | बढ़ाया | घटा हुआ | शुद्ध शेयर परिवर्तन |
|---|---|---|---|---|
| 55 (-22 पिछली तिमाही की तुलना में) | 34 (-5 पिछली तिमाही की तुलना में) | 137 (+20 पिछली तिमाही की तुलना में) | 87 (+8 पिछली तिमाही की तुलना में) | +4.1M |
Q1 2026 की तुलना में। SEC फॉर्म 13F फाइलिंग तिमाही के अंत के 45 दिनों के भीतर देय होती है, साथ ही देर से फाइल करने वालों के लिए एक छोटा बफर भी होता है — उस विंडो के भीतर आने वाली तिमाहियों को सबसे हालिया पूरी तरह से रिपोर्ट की गई जोड़ी के पक्ष में छोड़ दिया जाता है।
| संस्था | मूल्य | शेयर | % ट्रैक किए गए 13F का | प्रकार |
|---|---|---|---|---|
| BlackRock, Inc. | $238930360 | 23893036 | 8.46% | शेयर |
| VANGUARD GROUP INC | $173732325 | 22273375 | 6.15% | शेयर |
| RA CAPITAL MANAGEMENT, L.P. | $158271860 | 15827186 | 5.61% | शेयर |
| STATE STREET CORP | $151910980 | 15191098 | 5.38% | शेयर |
| DEERFIELD MANAGEMENT COMPANY, L.P. | $150964030 | 15096403 | 5.35% | शेयर |
| VANGUARD CAPITAL MANAGEMENT LLC | $113642360 | 11364236 | 4.03% | शेयर |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $111391580 | 11139158 | 3.95% | शेयर |
| TCG Crossover Management, LLC | $110209680 | 11020968 | 3.90% | शेयर |
| PERCEPTIVE ADVISORS LLC | $103088880 | 10308888 | 3.65% | शेयर |
| JANUS HENDERSON GROUP PLC | $84853520 | 8908506 | 3.01% | शेयर |
| Vestal Point Capital, LP | $83000000 | 8300000 | 2.94% | शेयर |
| TWO SIGMA INVESTMENTS, LP | $67753490 | 6775349 | 2.40% | शेयर |
| GEODE CAPITAL MANAGEMENT, LLC | $62493232 | 6248046 | 2.21% | शेयर |
| Aberdeen Group plc | $53108710 | 5310871 | 1.88% | शेयर |
| UBS Group AG | $50782800 | 5078280 | 1.80% | शेयर |
| BANK OF AMERICA CORP /DE/ | $48012840 | 4801284 | 1.70% | शेयर |
| GOLDMAN SACHS GROUP INC | $44818738 | 4481874 | 1.59% | शेयर |
| Frazier Life Sciences Management, L.P. | $40092400 | 4009240 | 1.42% | शेयर |
| Nuveen, LLC | $40072370 | 4007237 | 1.42% | शेयर |
| MILLENNIUM MANAGEMENT LLC | $33947290 | 3394729 | 1.20% | शेयर |
| TWO SIGMA ADVISERS, LP | $31895074 | 4089112 | 1.13% | शेयर |
| RP Management, LLC | $28846155 | 3846154 | 1.02% | शेयर |
| JANE STREET GROUP, LLC | $27626830 | 2762683 | 0.98% | शेयर |
| DIMENSIONAL FUND ADVISORS LP | $27187810 | 2718781 | 0.96% | शेयर |
| Fisher Asset Management, LLC | $26040270 | 2604027 | 0.92% | शेयर |
| RENAISSANCE TECHNOLOGIES LLC | $25302900 | 2530290 | 0.90% | शेयर |
| Kynam Capital Management, LP | $25226600 | 2522660 | 0.89% | शेयर |
| Candriam S.C.A. | $25125293 | 2514949 | 0.89% | शेयर |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $23532910 | 2353291 | 0.83% | शेयर |
| RICE HALL JAMES & ASSOCIATES, LLC | $23320430 | 2332043 | 0.83% | शेयर |
| NORTHERN TRUST CORP | $22557310 | 2255731 | 0.80% | शेयर |
| AQR CAPITAL MANAGEMENT LLC | $22143020 | 2214302 | 0.78% | शेयर |
| MORGAN STANLEY | $19996852 | 1999684 | 0.71% | शेयर |
| Nantahala Capital Management, LLC | $19011600 | 1901160 | 0.67% | शेयर |
| Eversept Partners, LP | $18656530 | 1865653 | 0.66% | शेयर |
| ORBIMED ADVISORS LLC | $18520000 | 1852000 | 0.66% | शेयर |
| HEALTHCARE OF ONTARIO PENSION PLAN TRUST FUND | $18449120 | 1844912 | 0.65% | शेयर |
| STIFEL FINANCIAL CORP | $18262340 | 1826234 | 0.65% | शेयर |
| VANGUARD FIDUCIARY TRUST CO | $17595730 | 1759573 | 0.62% | शेयर |
| CITADEL ADVISORS LLC | $17591600 | 1759160 | 0.62% | शेयर |
| JUPITER ASSET MANAGEMENT LTD | $16428740 | 1642874 | 0.58% | शेयर |
| IMC-Chicago, LLC | $16343360 | 1634336 | 0.58% | शेयर |
| Parkman Healthcare Partners LLC | $16242790 | 1624279 | 0.58% | शेयर |
| Legal & General Group Plc | $14555141 | 1455514 | 0.52% | शेयर |
| OP Asset Management Ltd | $13409900 | 1340990 | 0.48% | शेयर |
| Invesco Ltd. | $12337830 | 1233783 | 0.44% | शेयर |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $11956510 | 1195651 | 0.42% | शेयर |
| Pictet Asset Management Holding SA | $11951392 | 1249771 | 0.42% | शेयर |
| BNP PARIBAS FINANCIAL MARKETS | $11740520 | 1174052 | 0.42% | शेयर |
| FIRST TRUST ADVISORS LP | $11204690 | 1120469 | 0.40% | शेयर |
कार्यकर्ता और 5%+ मालिक 15 होल्डिंग्स
जिन निवेशकों ने SEC शेड्यूल 13D दाखिल किया है — जारीकर्ता को प्रभावित करने के इरादे से 5% से अधिक लाभकारी स्वामित्व (कार्यकर्ता दांव, बोर्ड अभियान, M&A)। प्रत्येक पंक्ति उस फाइलर की स्थिति की सबसे हालिया ज्ञात स्थिति दिखाती है।
| फाइलर | दाखिल किया | दांव | स्थिति | उद्देश्य | फाइलिंग |
|---|---|---|---|---|---|
| Great Point Partners, LLC, Dr. Jeffrey R. Jay, M.D., Mr. David Kroin ×3 फाइलिंग | 31 जुलाई 2018 | · | प्रारंभिक फाइलिंग | · | SEC |
| RA Capital Management, LLC, Peter Kolchinsky, RA Capital Healthcare Fund, L.P. | 2 अप्रैल 2018 | · | प्रारंभिक फाइलिंग | निष्क्रिय निवेश | SEC |
| Baker Bros. Advisors LP, Baker Bros. Advisors (GP) LLC, Julian C. Baker, Felix J. Baker ×5 फाइलिंग | 16 अगस्त 2016 | · | प्रारंभिक फाइलिंग | · | SEC |
| Baker Bros. Advisors, LLC, Julian C. Baker, Felix J. Baker ×2 फाइलिंग | 23 अक्टूबर 2012 | · | प्रारंभिक फाइलिंग | M&A / बिक्री | SEC |
| Julian C. Baker, Felix J. Baker ×4 फाइलिंग | 13 अक्टूबर 2011 | · | प्रारंभिक फाइलिंग | · | SEC |
| L. John Doerr III, KPCB Pandemic and Bio Defense Fund, LLC, KPTV, LLC ×2 फाइलिंग | 20 अगस्त 2007 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 7 दिसमबर 2005 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 7 दिसमबर 2005 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 7 दिसमबर 2005 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति | 13 अक्टूबर 2005 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 26 फ़रवरी 2004 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 25 फ़रवरी 2004 | · | प्रारंभिक फाइलिंग | · | SEC |
| अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति, अघोषित रिपोर्टिंग व्यक्ति | 24 फ़रवरी 2004 | · | प्रारंभिक फाइलिंग | · | SEC |
| Biotechnology Value Fund, L.P., Investment 10, L.L.C., Biotechnology Value Fund II, L.P., BVF Investments, L.L.C., BVF Partners L.P., BVF Inc. ×2 फाइलिंग | 31 अक्टूबर 2003 | · | प्रारंभिक फाइलिंग | · | SEC |
| William W. Featheringill | 14 फ़रवरी 2002 | · | प्रारंभिक फाइलिंग | · | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
कंपनी के अंदरूनी सूत्र 51 इनसाइडर्स · 21 अधिकारी · 30 निदेशक
| अंदरूनी | भूमिका | अंतिम गतिविधि | शेयरों का स्वामित्व | खरीद 12m | बिक्री 12m | नेट 12m |
|---|---|---|---|---|---|---|
| Babar Ghias | Chief Financial Officer | 17 दिसमबर 2025 A | 268700 | 0 | 0 | $0 |
| Anthony Doyle | Chief Financial Officer | 19 दिसमबर 2024 A | 377867 | 0 | 0 | $0 |
| Thomas R Staab II | Senior Vice President and CFO | 21 फ़रवरी 2020 A | 125176 | 0 | 0 | $0 |
| Stuart Grant | SR VP & CFO | 16 मार्च 2011 M | 57102 | 0 | 0 | $0 |
| Charles K Gayer | President and CCO | 22 दिसमबर 2025 M | 952583 | 0 | 0 | $0 |
| Claude J Bennett | Chief Operating Officer | 14 मार्च 2008 A | 65730 | 0 | 0 | $0 |
| Alane P Barnes | Chief Legal Officer | 13 मई 2026 M | 400703 | 0 | 7 | $-3461969 |
| Sandeep Menon | Chief R&D Officer | 6 अप्रैल 2026 A | 205150 | 0 | 0 | $0 |
| Helen M. Thackray | Chief R&D Officer | 31 मार्च 2025 F | 377318 | 0 | 0 | $0 |
| Michael L Jones | Exec. Director, Finance - PAO | 19 दिसमबर 2022 A | 16653 | 0 | 0 | $0 |
| Yarlagadda S Babu | Chief Discovery Officer | 14 नवमबर 2022 M | 298541 | 0 | 0 | $0 |
| William P Sheridan | Chief Medical Officer | 10 मार्च 2022 M | 37954 | 0 | 0 | $0 |
| Megan Sniecinski | Chief Business Officer | 15 दिसमबर 2020 A | 45000 | 0 | 0 | $0 |
| Lynne Powell | Senior VP - CCO | 28 जनवरी 2019 M | 0 | 0 | 0 | $0 |
| David Mccullough | VP | 15 मार्च 2012 F | 24124 | 0 | 0 | $0 |
| Robert S Lowrey | Controller, PAO | 7 फ़रवरी 2011 A | 9766 | 0 | 0 | $0 |
| Mike Mills | Principal Accounting Officer | 12 मार्च 2010 M | 0 | 0 | 0 | $0 |
| Michael A Darwin | Principal Accounting Officer | 31 जुलाई 2008 P | 3048 | 0 | 0 | $0 |
| Jonathan M Nugent | VP Corp Communications | 31 जुलाई 2007 P | 508 | 0 | 0 | $0 |
| James W Alexander | SR. VP, Chief Medical Officer | 31 जुलाई 2007 P | 3659 | 0 | 0 | $0 |
| Randall B Riggs | Senior VP Business Development | 16 मई 2007 A | 1928 | 0 | 0 | $0 |
| Amy E Mckee | निदेशक | 31 अगस्त 2026 A | 47821 | 0 | 1 | $-100285 |
| Jill C. Milne | निदेशक | 31 अगस्त 2026 A | 33226 | 0 | 0 | $0 |
| Steven Frank | निदेशक | 31 अगस्त 2026 A | 36747 | 0 | 0 | $0 |
| Jon P Stonehouse | निदेशक | 31 अगस्त 2026 A | 1340419 | 0 | 0 | $0 |
| Vincent Milano | निदेशक | 31 अगस्त 2026 A | 109642 | 0 | 0 | $0 |
| Theresa Heggie | निदेशक | 11 जून 2026 A | 80646 | 0 | 1 | $-504823 |
| Machelle Sanders | निदेशक | 11 जून 2026 A | 45936 | 0 | 1 | $-68544 |
| Steven K Galson | निदेशक | 11 जून 2026 A | 27794 | 0 | 0 | $0 |
| Alan G Levin | निदेशक | 11 जून 2026 A | 79565 | 0 | 0 | $0 |
| Nancy J Hutson | निदेशक | 12 जून 2025 A | 99138 | 0 | 0 | $0 |
| George B Abercrombie | निदेशक | 12 जून 2024 A | 36431 | 0 | 0 | $0 |
| Steve Aselage | निदेशक | 12 जून 2024 A | 70159 | 0 | 0 | $0 |
| Kenneth B Lee JR | निदेशक | 13 जून 2023 A | 68863 | 0 | 0 | $0 |
| Robert Alexander Ingram | निदेशक | 28 फ़रवरी 2023 A | 100198 | 0 | 0 | $0 |
| Stanley C Erck | निदेशक | 28 नवमबर 2018 M | 48333 | 0 | 0 | $0 |
| Fred Cohen | निदेशक | 20 जून 2018 A | 119410 | 0 | 0 | $0 |
| Sanj K Patel | निदेशक | 24 मई 2017 A | · | 0 | 0 | $0 |
| Charles A Sanders | निदेशक | 29 फ़रवरी 2016 A | 12971 | 0 | 0 | $0 |
| Peder Jensen | निदेशक | 2 मई 2014 A | 60000 | 0 | 0 | $0 |
| John L Higgins | निदेशक | 23 मई 2012 A | · | 0 | 0 | $0 |
| HOROVITZ ZOLA P | निदेशक | 23 मई 2012 A | 3000 | 0 | 0 | $0 |
| Stephen R Biggar | निदेशक | 12 मई 2011 A | · | 0 | 0 | $0 |
| Beth C Seidenberg | निदेशक | 13 मई 2010 A | 3000 | 0 | 0 | $0 |
| William W Featheringill | निदेशक | 13 मई 2010 A | 231538 | 0 | 0 | $0 |
| William M Spencer III | निदेशक | 16 मई 2007 A | 186761 | 0 | 0 | $0 |
| Joseph H Sherrill JR | निदेशक | 16 मई 2007 A | 451900 | 0 | 0 | $0 |
| Charles E Bugg | निदेशक | 18 मार्च 2007 A | 62439 | 0 | 0 | $0 |
| GORDON CARL L | निदेशक | 17 मई 2006 A | 1100000 | 0 | 0 | $0 |
| John A Montgomery | निदेशक | 4 नवमबर 2003 M | 46785 | 0 | 0 | $0 |
| Randolph C Steer | · | 21 मई 2008 A | · | 0 | 0 | $0 |
SEC फॉर्म 3/4/5 फाइलिंग से अंदरूनी सूत्र; नेट = केवल ओपन-मार्केट P/S
ईटीएफ स्वामित्व 41 ETFs द्वारा धारित
वजन केवल प्रत्यक्ष इक्विटी होल्डिंग्स (N-PORT) को दर्शाता है; लीवरेज्ड या डेरिवेटिव-आधारित फंड में अतिरिक्त स्वैप एक्सपोजर हो सकता है जो नहीं दिखाया गया है।
| फंड | भार | इकाइयाँ | तिथि अनुसार | स्रोत |
|---|---|---|---|---|
| PBE · Invesco Exchange-Traded Fund Trust | 2.34% | 1193733 SH | 2 अक्टूबर 2026 | दैनिक |
| BBP · ETFis Series Trust I | 1.42% | 155993 NS | 31 जुलाई 2026 | N-PORT |
| ABLS · Abacus FCF ETF Trust | 0.99% | 510 NS | 31 जुलाई 2026 | N-PORT |
| JSMD · Janus Detroit Street Trust | 0.92% | 1078429 NS | 31 जुलाई 2026 | N-PORT |
| JSML · Janus Detroit Street Trust | 0.62% | 248560 NS | 31 जुलाई 2026 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.59% | 324702 NS | 31 जुलाई 2026 | N-PORT |
| FYC · First Trust Exchange-Traded AlphaDE… | 0.36% | 516595 NS | 31 जुलाई 2026 | N-PORT |
| OMFS · Invesco Exchange-Traded Self-Indexe… | 0.22% | 73039 SH | 2 अक्टूबर 2026 | दैनिक |
| PWS · Pacer Funds Trust | 0.17% | 4436 NS | 31 जुलाई 2026 | N-PORT |
| VTWG · VANGUARD SCOTTSDALE FUNDS | 0.14% | 249665 SH | 19 अगस्त 2026 | दैनिक |
| ESSC · Strategy Shares | 0.14% | 5593 NS | 31 जुलाई 2026 | N-PORT |
| IBBQ · Invesco Exchange-Traded Fund Trust … | 0.14% | 18119 SH | 2 अक्टूबर 2026 | दैनिक |
| IBB · iShares Trust | 0.13% | 1651139 SH | 11 सितमबर 2026 | दैनिक |
| IWO · iShares Trust | 0.13% | 2178966 SH | 11 सितमबर 2026 | दैनिक |
| FYX · First Trust Exchange-Traded AlphaDE… | 0.11% | 174467 NS | 31 जुलाई 2026 | N-PORT |
| BBSC · J.P. Morgan Exchange-Traded Fund Tr… | 0.08% | 64429 NS | 31 जुलाई 2026 | N-PORT |
| FAD · First Trust Exchange-Traded AlphaDE… | 0.07% | 46799 NS | 31 जुलाई 2026 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.07% | 1339774 SH | 19 अगस्त 2026 | दैनिक |
| RSSL · Global X Funds | 0.07% | 111471 NS | 31 जुलाई 2026 | N-PORT |
| ISCG · iShares Trust | 0.06% | 75067 SH | 11 सितमबर 2026 | दैनिक |
| IWM · iShares Trust | 0.06% | 5937121 SH | 11 सितमबर 2026 | दैनिक |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.06% | 202979 SH | 2 अक्टूबर 2026 | दैनिक |
| DFAS · Dimensional ETF Trust | 0.05% | 770732 NS | 31 जुलाई 2026 | N-PORT |
| VBK · VANGUARD INDEX FUNDS | 0.04% | 1696014 SH | 19 अगस्त 2026 | दैनिक |
| VXF · VANGUARD INDEX FUNDS | 0.03% | 2837341 SH | 19 अगस्त 2026 | दैनिक |
| VHT · VANGUARD WORLD FUND | 0.03% | 624412 SH | 19 अगस्त 2026 | दैनिक |
| FHLC · FIDELITY COVINGTON TRUST | 0.03% | 99007 NS | 31 जुलाई 2026 | N-PORT |
| VB · VANGUARD INDEX FUNDS | 0.02% | 2922024 SH | 19 अगस्त 2026 | दैनिक |
| WSML · iShares Trust | 0.01% | 11812 SH | 11 सितमबर 2026 | दैनिक |
| IWV · iShares Trust | 0.00% | 72998 SH | 11 सितमबर 2026 | दैनिक |
| ITOT · iShares Trust | 0.00% | 336323 SH | 11 सितमबर 2026 | दैनिक |
| DFUS · Dimensional ETF Trust | 0.00% | 52194 NS | 31 जुलाई 2026 | N-PORT |
| DFAC · Dimensional ETF Trust | 0.00% | 36571 NS | 31 जुलाई 2026 | N-PORT |
| TILT · FlexShares Trust | 0.00% | 632 NS | 31 जुलाई 2026 | N-PORT |
| DCOR · Dimensional ETF Trust | 0.00% | 286 NS | 31 जुलाई 2026 | N-PORT |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 8070274 SH | 19 अगस्त 2026 | दैनिक |
| VT · VANGUARD INTERNATIONAL EQUITY INDEX… | 0.00% | 196622 SH | 19 अगस्त 2026 | दैनिक |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 19676 SH | 19 अगस्त 2026 | दैनिक |
| ESGV · VANGUARD WORLD FUND | 0.00% | 51624 SH | 19 अगस्त 2026 | दैनिक |
| ISCB · iShares Trust | · | 10494 SH | 11 सितमबर 2026 | दैनिक |
| SMLF · iShares Trust | · | 766086 SH | 11 सितमबर 2026 | दैनिक |
BCRX विश्लेषक सर्वसम्मति तेजी और मंदी के विश्लेषक राय, 12-महीने का मूल्य लक्ष्य, अपसाइड
रेटिंग · 17 विश्लेषक
खरीदें
मध्यिका लक्ष्य
$17.00
+108.1%
5 29.4%
मजबूत खरीद
10 58.8%
खरीदें
2 11.8%
होल्ड
0 0.0%
बेचें
0 0.0%
मजबूत बिक्री
12-महीने का मूल्य लक्ष्य
11 विश्लेषक · 2026-09-28माध्य लक्ष्य $20.64 +152.6%
← सभी लक्ष्यों से नीचे
वर्तमान मूल्य $8.17
निम्न$11.00
माध्य$20.64
उच्च$32.00
सहकर्मी तुलना (GICS उप-उद्योग) प्रमुख मेट्रिक्स बनाम सेक्टर के साथी
वित्तीय वर्ष के आधार पर, प्रत्येक कंपनी के पिछले वित्तीय वर्ष के अंत के बंद भाव के अनुसार कीमतें।
| टिकर | मार्केट कैप | P/E | राजस्व YoY | शुद्ध मार्जिन | ROE | सकल मार्जिन |
|---|---|---|---|---|---|---|
| BCRX | $1.66B | 6.4 | 94.1% | 30.2% | -97.6% | · |
| RXRX | $2.16B | -2.8 | 26.9% | -863.4% | -62.9% | · |
| VERA | · | -10.9 | · | · | -55.9% | · |
| MLYS | $2.96B | -15.8 | · | · | -32.2% | · |
| ZBIO | $1.98B | -4.3 | 100.0% | -3777.4% | -156.8% | · |
| VCEL | $1.82B | 112.5 | 16.4% | 6.0% | 5.0% | 74.4% |
| BHVN | $1.50B | -1.6 | · | · | -310.8% | · |
| AGIO | $1.59B | -3.8 | 48.0% | -764.0% | -32.2% | · |
| VIR | $841M | -1.9 | -7.6% | -638.9% | -51.1% | · |
| PVLA | $1.30B | -28.2 | 65.3% | -1610.6% | -110.1% | · |
ताज़ा समाचार इस कंपनी का उल्लेख करने वाली हालिया सुर्खियां
RBC Capital ने बायोटेक के Q1 2026 परिणाम पूर्वावलोकन के हिस्से के रूप में BioCryst Pharmaceuticals (BCRX) का PT बढ़ाया।
Yahoo Finance · 5 months पहले
BioCryst (BCRX) अधिग्रहण की खबरों पर 7.10% में वृद्धि करता है
Yahoo Finance · 6 months, 1 week पहले
BioCryst Pharmaceuticals, Inc. (BCRX) एक अच्छी स्टॉक खरीदने के लिए?
Yahoo Finance · 6 months, 1 week पहले
मेरे मेट्रिक्स आपकी व्यक्तिगत वॉचलिस्ट — पूर्ण फंडामेंटल से चयनित पंक्तियाँ
उन मेट्रिक्स को चुनें जो आपके लिए मायने रखते हैं — ऊपर फुल फंडामेंटल्स में किसी भी पंक्ति के बगल में + पर क्लिक करें।
आपका चयन सहेजा गया है और यह सभी टिकर में आपके साथ रहता है।
स्रोत: SEC 10-Q अग 5, 2026 को फाइल किया गया